Partner Article
America beckons for Onyx following major appointment
DRUG research firm Onyx Scientific has set out plans to grow its US presence after appointing a new business development director with global pedigree.
The £4m-a-year Sunderland company currently conducts around 25% of its business in North America – the world’s largest pharmaceutical market.
It is now aiming to step up its operations stateside with the appointment of Craig Loftus as director of new business development to drive its ambitious plans.
Mr Loftus has 25 years of commercial experience working for several large outfits including GE, Merck, Millpore and Stedim.
He said: “I am excited about working for such a high quality company as Onyx Scientific and am looking forward to leveraging previous relationships.
Managing director Dr Tony Flinn said: “Our ambition is to really grow the business as aggressively as we can, especially in the important US market. We have around 25% of business in the US and we hope to do more.”
This was posted in Bdaily's Members' News section by Ruth Mitchell .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
The missing piece of the puzzle in the NEET crisis
The North East investment story needs two engines
We must forge change to close the skills gap
Creating the conditions for North East talent to thrive
Time to end London monopoly on arts talent
Why local government is key to devolution success
Your reputation is worth more than that invoice
There is no perfect time when selling a business
What next when social media career help goes?
The psychological contract that nobody signs
Time for strategy built on the foundational economy
Why being ‘work-ready’ matters more than ever